STIM1ins Isoform Biomarker for Splicing Defect Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective biomarkers and treatments for cancers associated with splicing defects, particularly those involving mutations in genes like SF3B1, which affect splicing regulation and lead to aberrant transcripts and protein isoforms, complicating diagnosis and treatment in conditions such as myelodysplastic syndromes and chronic lymphocytic leukemia.
Innovation Solution
Identification and utilization of a new splice variant of STIM1, called STIM1ins, as a biomarker for diagnosis, prognosis, and treatment response, along with the development of specific antibodies and inhibitors targeting this isoform to modulate its expression or activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If alternative splicing mechanisms are utilized to create multiple proteins from the same gene, then proteome diversity is increased, but splicing deregulation leads to aberrant transcripts and diagnostic complexity
Solution Approach 1:
The patent segments the STIM1 gene transcript into multiple isoforms (STIM1-S, STIM1-L, STIM1ins) with distinct functional properties. The novel STIM1ins isoform contains an additional insert sequence that creates a unique protein variant, allowing the system to maintain proteome diversity while establishing clear diagnostic markers for different splicing states.
Solution Approach 2:
The patent applies local quality by creating the STIM1ins isoform with a specific insert sequence (SEQ ID NO: 3) at a defined location within the transcript. This localized modification produces a protein isoform with altered properties compared to the canonical STIM1, enabling specific targeting and detection without affecting other splicing events system-wide.
2Productivity
If splicing factors are mutated to produce aberrant transcripts, then cancer progression is driven, but detection and treatment precision is reduced
Solution Approach 1:
The patent uses the STIM1ins isoform as an intermediary marker that indirectly reports on SF3B1 mutation status and splicing defect presence. Rather than directly detecting the mutation or aberrant splicing machinery, the assay targets the resulting protein isoform, providing a precise and specific diagnostic readout for cancers with splicing defects.
Solution Approach 2:
The patent employs antibodies with high specificity for the STIM1ins isoform that enable clear visual or detectable differentiation between cancer cells expressing the aberrant isoform and normal cells. This specific binding creates a distinct detectable signal that precisely identifies the presence of splicing-defect-driven cancer.
3Quantity of substance
If canonical STIM1 antibodies are used for detection, then general STIM1 expression is detected, but specific isoform identification is lost
Solution Approach 1:
The patent extracts and targets the unique insert sequence (SEQ ID NO: 3) that is present in the STIM1ins isoform but absent from canonical STIM1 isoforms. By designing antibodies that specifically recognize this extracted unique region, the system maintains the ability to detect STIM1 expression while achieving precise isoform identification through the specific binding to the insert sequence.
Data Source
AI summary
The present invention relates to the identification of a new splice variant of STIM1 useful as a biomarker and as a target for the treatment of diseases.